TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

R J Gralla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.